Evidence map›Paper›PMID 34172584›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Structural differences in the FAD-binding pockets and lid loops of mammalian CRY1 and CRY2 for isoform-selective regulation.

Simon Miller, Ashutosh Srivastava, Yoshiko Nagai, Yoshiki Aikawa, Florence Tama, Tsuyoshi Hirota

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Targeting Cryptochromes in Chronic Diseases.Cell biology international · 2025
    Review
  6. Article
  7. Article
  8. Rational Design of a Flavoenzyme for Aerobic Nicotine Catabolism.bioRxiv : the preprint server for biology · 2024
    Article
  9. A structural decryption of cryptochromes.Frontiers in chemistry · 2024
    Review
  10. Article
  11. Article
  12. CRY2 isoform selectivity of a circadian clock modulator with antiglioblastoma efficacy.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  13. Time to target the circadian clock for drug discovery.Trends in biochemical sciences · 2022
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Simon MillerInstitute of Transformative Bio-Molecules, Nagoya University, 464-8601 Nagoya, Japan.ORCID 0000-0002-6481-5917
Ashutosh SrivastavaInstitute of Transformative Bio-Molecules, Nagoya University, 464-8601 Nagoya, Japan.ORCID 0000-0001-9820-720X
Yoshiko NagaiInstitute of Transformative Bio-Molecules, Nagoya University, 464-8601 Nagoya, Japan.
Yoshiki AikawaInstitute of Transformative Bio-Molecules, Nagoya University, 464-8601 Nagoya, Japan.
Florence TamaInstitute of Transformative Bio-Molecules, Nagoya University, 464-8601 Nagoya, Japan.
Tsuyoshi HirotaInstitute of Transformative Bio-Molecules, Nagoya University, 464-8601 Nagoya, Japan; thirota@itbm.nagoya-u.ac.jp.ORCID 0000-0003-4876-3608
Nagoya University · JPIndian Institute of Technology Gandhinagar · INRIKEN Center for Computational Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The circadian clock is a biological timekeeper that operates through transcription-translation feedback loops in mammals. Cryptochrome 1 (CRY1) and Cryptochrome 2 (CRY2) are highly conserved core clock components having redundant and distinct functions. We recently identified the CRY1- and CRY2-selective compounds KL101 and TH301, respectively, which provide useful tools for the exploration of isoform-selective CRY regulation. However, intrinsic differences in the compound-binding FAD (flavin adenine dinucleotide) pockets between CRY1 and CRY2 are not well understood, partly because of nonoptimal properties of previously reported apo form structures in this particular region constituted by almost identical sequences. Here, we show unliganded CRY1 and CRY2 crystal structures with well-defined electron densities that are largely free of crystal contacts at the FAD pocket and nearby lid loop. We revealed conformational isomerism in key residues. In particular, CRY1 W399 and corresponding CRY2 W417 in the FAD pocket had distinct conformations ("out" for CRY1 and "in" for CRY2) by interacting with the lid loop residues CRY1 Q407 and CRY2 F424, respectively, resulting in different overall lid loop structures. Molecular dynamics simulations supported that these conformations were energetically favorable to each isoform. Isoform-selective compounds KL101 and TH301 preferred intrinsic "out" and "in" conformations of the tryptophan residue in CRY1 and CRY2, respectively, while the nonselective compound KL001 fit to both conformations. Mutations of lid loop residues designed to perturb their isoform-specific interaction with the tryptophan resulted in reversed responses of CRY1 and CRY2 to KL101 and TH301. We propose that these intrinsic structural differences of CRY1 and CRY2 can be targeted for isoform-selective regulation.

Indexed as

AnimalsBinding SitesCryptochromesCrystallography, X-RayFlavin-Adenine DinucleotideMammalsMolecular Dynamics SimulationMutationProtein IsoformsProtein Structure, SecondaryCry1 protein, mouseCry2 protein, mouseCryptochromesFlavin-Adenine DinucleotideProtein Isoformscircadian clockcryptochromesmolecular dynamics simulationsmall-molecule modulatorsX-ray crystallography

Identifiers

PMID34172584
PMCPMC8255803
OpenAlexW3174528376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.